Home › Companies › CING

Cingulate

Market cap $70.6M 15.0M shares (10-Q, Nov 13, 2026) × $4.72 close Nov 17, 2026

Most recent annual filing: 2026-03-18

Pipeline (1 active programs)

Technology platforms

PTR · BDD Pharma

Precision Timed Release (PTR) drug delivery platform — proprietary multi-core tablet technology incorporating an Erosion Barrier Layer (EBL) to deliver precisely timed pulsatile drug releases; focus areas: ADHD and anxiety disorders. EBL formulation (Oralogik) licensed from BDD Pharma.

Precision Timed Release

PTR-enabled tri-modal release delivery platform for oral tablets; designed to provide morning onset and sustained active-day coverage in a single once-daily tablet; focus area: ADHD and potentially other CNS conditions

Precision Timed Release · BDD Pharma

PTR drug delivery platform incorporating a proprietary Erosion Barrier Layer (EBL) to control drug release at precise, pre-defined times; designed to enable true once-daily dosing; focus areas include ADHD and anxiety disorders. EBL formulation (Oralogik) licensed from BDD Pharma.

PTR

Precision Timed Release drug delivery platform incorporating a proprietary Erosion Barrier Layer for release of drug substance at specific, pre-defined time intervals, enabling once-daily multi-dose tablets; focus areas include ADHD and anxiety

Capital (as filed)

Cash
$23.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$7.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$23.2M cash, runway mid-2027 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (8)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (8 calls)

Every verdict Biotech Distilled has published on Cingulate, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Cingulate (CING) - Scientific Deep Dive on CTx-1301 and Pipeline Products Strong pharmacokinetic science but manufacturing risk from CDMO Form 483 and severe balance sheet risks make the stock too opaque to buy ahead of the May 31 PDUFA date.
  2. Avoid UPDATE: Cingulate (CING) - The Dilution Gap Just Became a Chasm The $100M ATM, Lincoln Park equity facility, and failed shareholder vote create a structural dilution ceiling that makes the equity a trap regardless of the underlying science.
  3. Avoid UPDATE: Cingulate (CING) - Institutional Adult Supervision Enters the Boardroom Falcon Creek's board seat provides slight oversight on dilution management but does not change the fundamental Sell/Avoid stance given the balance sheet minefield.
  4. Avoid UPDATE: Cingulate (CING) - The CMC Shoe Drops 17 Days Before PDUFA FDA's formal CMC information request buried in the 10-Q, a 64% share count explosion, and the Avondale CRL tripwire materially raise the probability of a PDUFA extension or CRL, reaffirming Sell/Avoid.
  5. Avoid UPDATE: Cingulate (CING) - The CRL Lands, the Tripwire Arms The FDA issued a CRL on CMC grounds, the Avondale deferral right is extinguished, and the toxic debt tripwire is now armed, validating the equity trap thesis.
  6. Watch UPDATE: Cingulate (CING) - The Resubmission Nobody Will Date Going-concern cliff pushed to mid-2027 and a wholly-owned U.S. patent to 2042 improve survival probability and M&A appeal enough to upgrade from Avoid to Watch, but no resubmission date and doubled share count keep it event-driven only.
  7. Watch UPDATE: Cingulate (CING) - The Resubmission Finally Gets a Date (But Not a Class) A December 2026–January 2027 resubmission window is real progress but the missing Class 1/2 designation and Q3 2027 launch guidance implying the slower 6-month clock running into the cash wall keep the stance at Watch.
  8. Watch UPDATE: Cingulate (CING) - A Second Salesman for the ATM Adding Maxim as a second ATM agent signals more dilutive share sales ahead of the resubmission classification, downgrading financial conviction further but keeping Watch as the Class 1/2 call still drives the outcome.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (42)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 14, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)